Botanix Pharmaceuticals Share Price and Company Fundamentals
Last traded: Today at 4:09 AM
Botanix Pharmaceuticals Limited, a clinical stage synthetic cannabinoid pharmaceutical company, engages in the research and development of dermatology and antimicrobial products in Australia. It offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which is in Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; and BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea. The company was incorporated in 1984 and is based in North Perth, Australia.
Key Metrics
PE ratio
-
PB ratio
3.04
Dividend yield
Beta
2.68
Market cap
$75.05M
Enterprise value
$62.84M
Company profile
| Primary activities | Pharmaceuticals. |
|---|---|
| Industry / Sector | Biotechnology / Healthcare |
| Full time employees | 1 |
| Website | http://www.botanixpharma.com |
| Mailing address | 50 Angove Street Level 1 North Perth WA 6006 Australia |
| Phone / Fax | 61 8 6555 2945 / 61 8 6210 1153 |
| Share registry | AUTOMIC REGISTRY SERVICES |
Dividends
Botanix Pharmaceuticals does not pay dividends.
Company Executives
As of May 2021, following are the company executives and directors listed on Botanix Pharmaceuticals.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Vincent P. Ippolito | MD, Pres & Exec. Chairman | 61 | 808.16k |
| Dr. Henry William Bosch | Chief Scientific Officer & Exec. Director | 140.72k | |
| Mr. Matthew Callahan L.L.B., M.B.A., MBA LLB | Exec. Director | 47 | 481.08k |
| Dr. Clarence L. Young | Chief Medical Officer | 64 | |
| Ms. Lynda Berne | Head of Commercial | ||
| Mr. Simon Robertson C.A., B.Bus, M Appl. Fin, CA | Company Sec. |
Profitability and management effectiveness
Profit margin
-131.65%
Operating margin
-132.33%
Return on assets
-18.31%
Return on equity
-31.28%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Botanix Pharmaceuticals is 75.05M and its enterprise value is 62.84M. The enterprise value to revenue ratio of BOT is 9.12.
The BOT's stocks Beta value is 2.68 making it 168% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Botanix Pharmaceuticals (BOT)
Botanix Pharmaceuticals (ASX:BOT) Frequently Asked Questions
1. What is Botanix Pharmaceuticals's Stock Symbol?
Botanix Pharmaceuticals trades on ASX under the ticker symbol "BOT".
2. What is Botanix Pharmaceuticals's stock price today?
One share of BOT stock can currently be purchased for approximately $0.079.
3. How can I contact Botanix Pharmaceuticals?
Botanix Pharmaceuticals's mailing address is 50 Angove Street Level 1 North Perth WA 6006 Australia. The company can be reached via phone at 61 8 6555 2945.
4. What is Botanix Pharmaceuticals's official website?
The official website of Botanix Pharmaceuticals is http://www.botanixpharma.com.
5. Which share registry manages Botanix Pharmaceuticals's stock?
Botanix Pharmaceuticals's stock is managed by AUTOMIC REGISTRY SERVICES.